• Users Online:1054
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2012  |  Volume : 6  |  Issue : 3  |  Page : 1-9

A multi-centric, double-blind randomized, homoeopathic pathogenetic trial of Buxus sempervirens


1 Central Council for Research in Homoeopathy, New Delhi, India
2 Drug Proving Research Unit of Homoeopathy, Kolkata, West Bengal, India
3 Regional Research Institute of Homoeopathy, Mumbai, India
4 Central Research Institute of Homoeopathy, Kottayam, Kerala, India

Correspondence Address:
Rajpal
Central Council for Research in Homeopathy, 61-65, Institutional Area, Janakpuri, New Delhi- 110 058
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


Rights and PermissionsRights and Permissions

Objective:To elicit the pathogenetic response of Buxus sempervirens Linn. in homoeopathic potencies on healthy human volunteers. Methodology: Buxus sempervirens drug was proved by the Central Council for Research in Homoeopathy (CCRH) through randomized, double-blind, placebo-controlled method. The proving was conducted at three centres during 2007-08. The drug was proved in 6 & 30 centesimal potencies on 57 apparently healthy volunteers, declared eligible after their pre-trial medical examination by the medical specialists and routine laboratory investigations. In its first phase of proving, volunteers were given 56 doses of placebo divided in 4 doses per day for 14 days. In the next two phases, 56 doses of pre-selected potencies or placebo as per the randomization were consumed in divided doses same as in first phase. The symptoms generated during the trial period were noted down by the volunteers and elaborated by the Proving Masters. The generated data of the drug from all three centres was compiled at the proving-cum-data processing cell at CCRH headquarters after de-coding. Observations:Out of 40 provers who were on actual drug trial, only 23 manifested symptoms. The drug was able to generate symptoms in both the potencies to every part of the body. Conclusion: The pathogenetic response elicited during the proving trial, expands the scope of use of the drug Buxus sempervirens and will benefit the research scholars and clinicians. The generated symptoms of this drug will carry more value when verified clinically.


[PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed995    
    Printed19    
    Emailed0    
    PDF Downloaded168    
    Comments [Add]    

Recommend this journal